NRIX · XBRL financial data

Nurix Therapeutics financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NRIX's year ends in late November)

In millions of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Revenue	18	30	39	77	—	—
Revenue from contracts with customers	—	—	39	77	55	84
Research and development	66	116	184	189	222	317
General and administrative	16	31	38	43	46	53
Total operating expenses	83	148	222	232	268	370
Operating income (loss)	(65)	(118)	(184)	(155)	(213)	(286)
Income tax expense (benefit)	(21)	0	0	0	0	1
Net income (loss)	(43)	(117)	(180)	(144)	(194)	(264)
Earnings per share, basic USD per share	—	(2.73)	(3.71)	(2.65)	(2.88)	(3.05)
Earnings per share, diluted USD per share	—	(2.73)	(3.71)	(2.65)	(2.88)	(3.05)
Weighted average shares, basic millions of shares	—	43	49	54	67	87
Weighted average shares, diluted millions of shares	—	43	49	54	67	87

Fiscal years (NRIX's year ends in late November)

In millions of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Cash and cash equivalents	119	81	64	55	110	247
Short-term investments	162	215	245	—	—	—
Marketable securities	—	215	245	—	—	—
Marketable securities, non-current	—	137	64	—	—	—
Accounts receivable	—	—	0	—	0	0
Prepaid and other current assets	6	9	9	8	10	14
Total current assets	298	311	318	296	619	607
Property and equipment, net	7	11	17	17	18	22
Right-of-use asset	—	14	12	31	28	51
Total assets	396	477	417	356	669	688
Accounts payable	3	7	5	6	11	11
Total current liabilities	45	66	71	87	96	86
Lease liability, non-current	—	9	6	23	20	53
Total liabilities	106	134	113	155	142	149
Accumulated deficit	(104)	(221)	(401)	(545)	(739)	(1,003)
Total stockholders' equity	290	342	304	200	527	539
Total liabilities and equity	396	477	417	356	669	688
Common shares outstanding (cover page) millions of shares	39	45	47	49	76	103

Fiscal years (NRIX's year ends in late November)

In millions of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Net income (loss)	(43)	(117)	(180)	(144)	(194)	(264)
Stock-based compensation	4	16	28	34	34	38
Net cash from operating activities	(0)	(84)	(160)	(81)	(173)	(249)
Purchases of property and equipment	5	6	12	8	9	14
Net cash from investing activities	(254)	(108)	27	68	(258)	148
Proceeds from issuing common stock	218	150	19	0	290	0
Net cash from financing activities	339	154	117	3	486	239
Net change in cash	85	(39)	(15)	(10)	55	137

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	70	27	2.6*	79.2M	—	Q3 FY26 10-QSep 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	217	not reported	(81)*	174.0M	9.7 quarters	Q3 FY26 10-QSep 30, 2026
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
Geron	69	60	10*	644.2M	—	Q3 FY26 10-QSep 30, 2026
Pacira BioSciences	247	177	50*	40.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 9:47 PM ET. The filing on SEC.gov is the record.